These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15148234)

  • 1. Treatment of Erdheim-Chester disease with cladribine: a rational approach.
    Myra C; Sloper L; Tighe PJ; McIntosh RS; Stevens SE; Gregson RH; Sokal M; Haynes AP; Powell RJ
    Br J Ophthalmol; 2004 Jun; 88(6):844-7. PubMed ID: 15148234
    [No Abstract]   [Full Text] [Related]  

  • 2. [Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review].
    Adam Z; Koukalová R; Sprláková A; Rehák Z; Cervinek L; Szturz P; Krejcí M; Pour L; Zahradová L; Moulis M; Prásek J; Chaloupka R; Hájek R; Mayer J
    Vnitr Lek; 2011 Jun; 57(6):576-89. PubMed ID: 21751544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature].
    Adam Z; Petrášová H; Řehák Z; Koukalová R; Krejčí M; Pour L; Vetešníková E; Čermák A; Ševčíková S; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2016; 62(10):820-832. PubMed ID: 27900869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erdheim-Chester disease presenting as periodontal disease: Experience of treatment with cladribine, interferon-a, local radiotherapy and anakinra.
    Blomstrand L; Thor A; Hagberg H
    Acta Oncol; 2016; 55(2):248-50. PubMed ID: 25902723
    [No Abstract]   [Full Text] [Related]  

  • 5. [PET-CT documented complete remission of Erdheim-Chester disease, lasting more than 4 years from treatment initiation with cladribine].
    Adam Z; Řehák Z; Koukalová R; Bortlíček Z; Krejčí M; Pour L; Szturz P; Prášek J; Nebeský T; Adamová Z; Král Z; Mayer J
    Vnitr Lek; 2014; 60(5-6):499, 501-11. PubMed ID: 24974755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erdheim-Chester disease: an aggressive systemic disease treated with cladribine with favorable outcome (a case report)].
    Lasri N; Lahlimi F; Tazi MI
    Pan Afr Med J; 2022; 42():32. PubMed ID: 35910054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality imaging showing complete cardiovascular involvement by Erdheim-Chester disease.
    Alharthi MS; Calleja A; Panse P; Appleton C; Jaroszewski DE; Tazelaar HD; Mookadam F
    Eur J Echocardiogr; 2010 Aug; 11(7):E25. PubMed ID: 20406735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.
    Goyal G; Shah MV; Call TG; Litzow MR; Hogan WJ; Go RS
    JAMA Oncol; 2017 Sep; 3(9):1253-1256. PubMed ID: 28253394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Erdheim-Chester disease with canakinumab.
    Tran TA; Pariente D; Guitton C; Delwail A; Barat-Houari M; Meinzer U
    Rheumatology (Oxford); 2014 Dec; 53(12):2312-4. PubMed ID: 25234662
    [No Abstract]   [Full Text] [Related]  

  • 10. Erdheim-Chester disease.
    Brychtová M; Vlachová M; Gregorová J; Krejčí M; Adam Z; Ševčíková S
    Klin Onkol; 2021; 34(6):434-439. PubMed ID: 34911328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR: a new target in Erdheim-Chester disease?
    Haroche J; Amoura Z
    Blood; 2015 Sep; 126(10):1151-2. PubMed ID: 26337348
    [No Abstract]   [Full Text] [Related]  

  • 12. Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone.
    Bourke SC; Nicholson AG; Gibson GJ
    Thorax; 2003 Nov; 58(11):1004-5. PubMed ID: 14586060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erdheim-Chester disease: characteristics and management.
    Munoz J; Janku F; Cohen PR; Kurzrock R
    Mayo Clin Proc; 2014 Jul; 89(7):985-96. PubMed ID: 24814521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide].
    Adam Z; Sprláková A; Rehák Z; Koukalová R; Szturz P; Krejcí M; Pour L; Zahradová L; Cervinek L; Kren L; Moulis M; Hermanová M; Mechl M; Prásek J; Hájek R; Král Z; Mayer J
    Klin Onkol; 2011; 24(5):367-81. PubMed ID: 22070019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy.
    Wang JN; Qiu Y; Niu N; Zhang Y; Li J; Zhou DB; Cao XX
    Acta Oncol; 2020 Mar; 59(3):302-305. PubMed ID: 31559889
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of 3 patients with Erdhiem-Chester disease with cladribin or cladribin in combination with cyclophosphamide. Case report and review of the therapy].
    Král Z; Řehák Z; Krejčí M; Koukalová R; Ševčíková S; Pour L; Krejčí M; Štork M; Sandecká V; Adam Z
    Vnitr Lek; 2021; 67(3):157-164. PubMed ID: 34171955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease.
    Goyal G; Shah MV; Call TG; Hook CC; Hogan WJ; Go RS
    Blood Cancer J; 2017 Dec; 7(12):647. PubMed ID: 29242623
    [No Abstract]   [Full Text] [Related]  

  • 18. Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.
    Roeser A; Cohen-Aubart F; Breillat P; Miyara M; Emile JF; Charlotte F; Donadieu J; Amoura Z; Haroche J
    Haematologica; 2019 Nov; 104(11):e502-e505. PubMed ID: 30923093
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
    Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
    BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recurrent pericardial effusion as first manifestation of Erdheim-Chester disease].
    Lutz SZ; Schmalzing M; Vogel-Claussen J; Adam P; May AE
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1952-6. PubMed ID: 21935854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.